The David Scheinberg Lab

The David Scheinberg Lab

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes passive agents (antibodies, targeted nano-devices, and ligands) and active agents (vaccines). An important goal is to take these new therapies into human clinical trials for testing.

We have developed alpha particle therapies, targeted beta emitters, oncogene product peptide vaccines, and are presently developing prototype targeted nano-machines. Recently, our lab developed a molecular nanogenerator that releases alpha particles inside cancer cells. This is now being tested in humans. Read full article in Science (Science. 2001;294;1537-1540.).

The David Scheinberg Lab

David A. Scheinberg, MD, PhD

Chair, Molecular Pharmacology & Chemistry Program, SKI; Director, Center for Experimental Therapeutics


Research Focus

Molecular Pharmacology and Chemistry Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
Read more


  • MD, PhD, Johns Hopkins University School of Medicine

Lab Members

Research Projects

Learn more